Skip to main content

Advertisement

SpringerLink
Log in

Chronic functional abdominal pain (CFAP)

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

  • Patients with chronic functional abdominal pain (CFAP) present particularly challenging management issues for primary care physicians and gastroenterologists.

  • A major objective in the care of patients with CFAP is to develop an understanding of this condition as a biopsychosocial disorder where symptoms can be attributed to “brain-gut” dysfunction rather than to a missed structurally based condition.

  • The foundation of any therapeutic strategy is the patient-physician partnership, probably the hardest element of treatment for most physicians.

  • All treatment programs should be based on a multi-component strategy, with the patient as a full partner. Realistic expectations should be agreed upon for “care” rather than “cure.” The patient’s preferences should be a major factor in the decision as to whether to recommend pharmacologic or psychological treatment, or a combination of the two.

  • Antidepressant drugs are increasingly being used in CFAP, and well-designed studies are emerging to confirm their clinical effectiveness.

  • Patients’ understanding of the indications for and effects of antidepressants must be reframed in order to address barriers and achieve adherence to therapy.

  • The clinical effectiveness of antidepressants can often only be assessed after 3 to 6 weeks of therapy. The side effects, which appear early, are usually transient and often disappear within 1 to 2 weeks.

  • There is no conclusive evidence that one antidepressant drug is more effective than others, although most studies have tested tricyclic agents. The most important factors in the choice of antidepressant medication are side-effect profile, physician familiarity and comfort with the drug, and cost.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Thompson WG, Longstreth G, Drossman A, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(suppl 2):II43-II47. An up-to-date review of CFAP, defined and described by the Rome working group subcommittee. Includes details on definition, diagnostic criteria, epidemiology, clinical evaluation, and treatment. An expanded version will soon appear as a book chapter.

    Article  PubMed  Google Scholar 

  2. Drossman DA, Li Z, Andruzzi E, et al.: US householder survey of functional GI disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993, 38:1569–1580.

    Article  PubMed  CAS  Google Scholar 

  3. Maxton DG, Whorwell PJ: Use of medical resources and attitudes to health care of patients with “chronic abdominal pain”. Br J Med Econ 1992, 2:75–79.

    Google Scholar 

  4. Drossman DA: Chronic functional abdominal pain. Am J Gastroenterol 1996, 91:2270–2281. A classic review of CFAP with in-depth discussions of pathophysiology, assessment, and treatment of chronic abdominal pain.

    PubMed  CAS  Google Scholar 

  5. Fields HL, Basbaum AI, Wall PD, Melzack R: Endogenous pain control mechanisms. In Textbook of Pain. Edited by Fields HL, Basbaum AI, Wall PD, Melzack R. New York: Livingston; 1984:142–152.

    Google Scholar 

  6. Drossman DA: Psychosocial factors in chronic functional abdominal pain. In Basic and Clinical Aspects of Chronic Abdominal Pain. Edited by Mayer EA, Raybould HE. New York: Elsevier Science; 1993:271–280.

    Google Scholar 

  7. Melzack R, Wall P: Gate-control and other mechanisms. In The Challenge of Pain. Edited by Melzack R, Wall P. London: Pelican Books; 1988:165.

    Google Scholar 

  8. Drossman DA: Gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998, 60:258–267.

    PubMed  CAS  Google Scholar 

  9. Zinn W: The empathic physician. Arch Intern Med 1984, 153:306–312.

    Article  Google Scholar 

  10. Toner BB, Segal ZV, Emmott S, et al.: Cognitive behavior group therapy for patients with irritable bowel syndrome. Int J Group Psychother 1998, 48:215–243.

    PubMed  CAS  Google Scholar 

  11. Keefe FJ, Dunsmore J, Burnett R: Behavioural and cognitive-behavioural approaches to chronic pain: recent advances and future directions. J Consult Clin Psychol 1992, 60:528–536.

    Article  PubMed  CAS  Google Scholar 

  12. Guthrie E, Creed F, Dawson D, Tomenson B: A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatr 1993, 163:315–321.

    CAS  Google Scholar 

  13. Whorwell PJ: Use of hypnotherapy in gastrointestinal disease. Br J Hosp Med 1991, 45:27–29.

    PubMed  CAS  Google Scholar 

  14. Blanchard EB, Schwarz SP, Neff DF: Two-year follow-up of behavioral treatment of irritable bowel syndrome. Behavior Therapy 1988, 19:67–73.

    Article  Google Scholar 

  15. Phillips SF, Wingate DL: Irritable bowel syndrome: clinical management. In Functional disorders of the Gut. Edited by Phillips SF, Wingate DL. London: Churchill Livingstone; 1998:298–318.

    Google Scholar 

  16. Drossman DA: Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995, 123:688–697. A detailed description of the psychosocial assessment of patients with functional GI disorders, and the patientphysician relationship.

    PubMed  CAS  Google Scholar 

  17. Drossman DA: Psychological sound bites: exercises in the patient-doctor relationship. Am J Gastroenterol 1997, 92:1418–1423.

    PubMed  CAS  Google Scholar 

  18. Farthing MJ: New drugs in the management of irritable bowel syndrome. Drugs 1998, 56:11–21.

    Article  PubMed  CAS  Google Scholar 

  19. Young E, Stoneham MD, Petruckevitch A, et al.: A population study of food intolerance. Lancet 1994, 343:1127–1130.

    Article  PubMed  CAS  Google Scholar 

  20. Veldhuyzen van Zenten SJO, Talley NJ, Bytzer P, et al.: Design of treatment trials for functional gastrointestinal disorders. Gut 1999, 45(suppl 2):II69-II77.

    Google Scholar 

  21. Rogers M, Cerda JJ: The narcotic bowel syndrome. Am J Gastroenterol 1989, 11:132–135.

    CAS  Google Scholar 

  22. Onghena P, Houdenhove BV: Antidepressant-induced analgesia in chronic nonmalignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992, 49:205–219.

    Article  PubMed  CAS  Google Scholar 

  23. Eisendrath SJ, Kodama KT: Fluoxetine management of chronic abdominal pain. Psychosomatics 1992, 33:229.

    Google Scholar 

  24. Clouse RE: Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994, 39:2352–2363.

    Article  PubMed  CAS  Google Scholar 

  25. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS: Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med 1998, 60:503–509. A meta-analysis of the use of antidepressant drugs for chronic pain disorders in various organ systems. The data relating to various functional disorders has implications for the treatment of CFAP.

    PubMed  CAS  Google Scholar 

  26. Richeimer SH, Bajwa ZH, Kahraman SS, et al.: Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain 1997, 13:324–329.

    Article  PubMed  CAS  Google Scholar 

  27. Jann MW, Jenike MA, Lieberman JA: The new psychopharmaceuticals. In Patient Care. Edited by Gregory T. 1994:47–61.

  28. Finley PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994, 28:1359–1369.

    PubMed  CAS  Google Scholar 

  29. Brown WA, Harrison W: Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatr 1995, 56:30–34.

    CAS  Google Scholar 

  30. Zarate CA, Kando JC, Tohen M: Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatr 1996, 57:67–71.

    CAS  Google Scholar 

  31. Drossman DA: Psychosocial factors in the care of patients with gastrointestinal disorders. In Textbook of Gastroenterology. Edited by Yamada T. Philadelphia: Lippincott; 1999:638–659. A textbook discussion of the psychosocial aspects of functional GI disorders with an emphasis on the biopsychosocial approach to diagnosis, assessment, and treatment.

    Google Scholar 

  32. Cyr M, Brown CS: Nefazodone: its place among antidepressants. Ann Pharmacother 1996, 30:1006–1012.

    PubMed  CAS  Google Scholar 

  33. Toner BB, Segal CV, Emmott SD, Myran D: Cognitive-Behavioral Treatment of Irritable Bowel Syndrome. New York: Guilford Publications, Inc; 1999. A recently published book with a theoretical discussion of the role of cognitive-behavioral therapy in functional GI disorders, and a practical guide to the application of this approach to patients with IBS. The book also contains a valuable discussion on gender-related issues in functional GI disorders.

    Google Scholar 

  34. Drossman SA, Leserman J, Nachman N, et al.: Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990, 113:828–833.

    PubMed  CAS  Google Scholar 

  35. Svedlund J: Psychotherapy in irritable bowel syndrome: a controlled outcome study. Acta Psychiatr Scand 1983, 67:7–86.

    Google Scholar 

  36. Der DF, Kewington P: Rational self-directed hypnotherapy: a treatment for panic attacks. Am J Clin Hypn 1990, 32:160–167.

    PubMed  CAS  Google Scholar 

  37. King JV: A holistic technique to lower anxiety: relaxation with guided imagery. J Holist Nurs 1988, 6:16–20.

    PubMed  CAS  Google Scholar 

  38. Whorwell P: Hypnotherapy in irritable bowel syndrome. Lancet 1989, 2:622.

    Article  Google Scholar 

  39. Prior A, Colgan SM, Whorwell PJ: Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut 1990, 31:896–898.

    PubMed  CAS  Google Scholar 

  40. Bernstein DA, Borkovec TD: Progressive Relaxation Training. Champaign: Champaign Illinois Research Press; 1973.

    Google Scholar 

  41. Whorwell PJ, Gonsalkorale W: Chronic abdominal pain. In Functional Disorders of the Gut. Edited by Phillips SF, Wingate DL. London: Churchill Livingstone; 1998:98–120. A discussion of chronic abdominal pain with an emphasis on practical treatment strategies based on the long-term experience of the authors with these patients, including psychological therapies and hypnotherapy.

    Google Scholar 

  42. Alexander-Williams J: Do adhesions cause pain? BMJ 1987, 294:659–660.

    Article  PubMed  CAS  Google Scholar 

  43. Ikard RW: There is no current indication for laparoscopic adhesiolysis to treat abdominal pain. South Med J 1992, 85:939–940.

    Article  PubMed  CAS  Google Scholar 

  44. Mayer EA, Lembo T, Chang L: Approaches to the modulation of abdominal pain. Can J Gastroenterol 1999, 13(suppl):65A-70A. A recent review of chronic abdominal pain and available treatment options.

    PubMed  Google Scholar 

  45. Junien J-L, Riviere P: The hypersensitive gut-peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995, 9:117–126.

    Article  PubMed  CAS  Google Scholar 

  46. Dapoigny M, Abitbol J-L, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Dig Dis Sci 1996, 40:2244–2248.

    Article  Google Scholar 

  47. Prior A, Read NW: Reduction of rectal sensitivity and post-prandial motility by granisetron a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7:175–180.

    Article  PubMed  CAS  Google Scholar 

  48. Camilleri M, Mayer EA, Drossman DA, et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149–1159.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, 84101, Beer-Sheva, Israel

    Ami D. Sperber MD, MSPH

Authors
  1. Ami D. Sperber MD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas A. Drossman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sperber, A.D., Drossman, D.A. Chronic functional abdominal pain (CFAP). Curr Treat Options Gastro 3, 315–327 (2000). https://doi.org/10.1007/s11938-000-0045-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-000-0045-4

Keywords

Search

Navigation